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Abstract
Peripheral blood stem cell (PBSC) mobilization, which uses plerixafor (AMD 3100), a newly developed specific
inhibitor of the CXCR4 receptor, in combination with granulocyte-colony stimulating factor(G-CSF), has been shown
to enhance the stem cell mobilization in adult patients, but pediatric data are scarce. We documented our
experience with this drug in 6 Korean pediatric patients who had failed in chemomobilization, using G-CSF, alone.
All patients were mobilized CD34
+ cells (median, 11.08 × 10
6/kg: range, 6.34-28.97 × 10
6/kg) successfully within 2
to 3 cycles of apheresis, without complications. A total of 7 autologous transplantations were performed, including
1 tandem transplantation. However, 2 patients with brain tumors showed severe pulmonary complications,
including spontaneous pneumomediastinum. This is the first study of PBSC mobilization with plerixafor in Asian
pediatric patients. Furthermore our study suggests that mobilization with plerixafor may be effective in Korean
pediatric patients, who have previously been heavily treated and have failed PBSC mobilization with classical
chemomobilization, using G-CSF. However, further studies are needed to examine the possible complications of
autologous transplantation, using a mobilized plerixafor product in children.
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Letter to the editor
Plerixafor has been introduced for the mobilization of
hematopoietic stem cells to peripheral blood, by inter-
fering with the SDF1-CXCR4 interaction. Although it
has been FDA-approved in adult patients with non-
Hodgkin lymphoma or multiple myeloma [1,2], the
pediatric data usage are scarce, particularly in Asian
children [3-8].
We retrospectively reviewed all 6 patients (3 males, 3
females), who received plerixafor-based mobilization at
o u rc e n t e ra f t e ro b t a i n i n gt he Institutional Review
Board approval (H-1108-103-374). They had all
previously failed peripheral blood stem cell (PBSC)
mobilization by chemotherapy and G-CSF. The patient’s
characteristics, previous treatments and mobilization
chemotherapies are shown. (Table 1) All patients
received G-CSF (10 μg/kg) for 4 days, without prior che-
motherapy. Then plerixafor (240 μg/kg; Mozobil, Gen-
zyme Inc, Naarden, The Netherlands) and G-CSF (10
μg/kg) were administered subcutaneously, at 10 and 2
hours before each apheresis. CD34
+ cells (median, 11.08
×1 0
6/kg; range, 6.34-28.97 × 10
6/kg) were mobilized
successfully in all patients, after 2 to 3 apheresis without
immediate complications (for each apheresis: mean, 6.28
×1 0
6/kg: range, 3.17-14.49 × 10
6/kg). Seven autologous
stem cell transplantations were performed, including 1
tandem transplantation, and the results of engraftment
were acceptable. (Table 2)
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any medium, provided the original work is properly cited.Patients #1, #3 and #6 were disease-free at the last fol-
low-up (28, 12 and 3 months after transplantation,
respectively), however, patient #4 died on day 3, due to
sudden cardiac arrest. Interestingly, two medulloblas-
toma patients (patients #2 and #5) showed serious lung
problems, which include spontaneous pneumomediasti-
num on day 56 and 11, died on day 102 and 89, respec-
tively. The cause of death of both patients showed to be
respiratory failure, of which, the pathogen was not
revealed by bronchoalveolarl a v a g eo rl u n gb i o p s y .T h e
pathologic finding was consistent with a diffuse alveolar
damage. In our center, 6 other patients who underwent
the same radiotherapy and autologous PBSC transplan-
tation, with the same conditioning regimen, but did not
receive plerixafor for mobilization, have not shown such
fatal pulmonary complication (data not shown). Due to
the plerixafor mobilization of the different cell popula-
tions, in comparison with G-CSF alone [9,10], unex-
pected complications might occur after infusion in
susceptible recipients, like the 2 patients that were men-
tioned above who underwent irradiation around the
thoracic area.
In conclusion, we report the first data of Asian pedia-
tric usage of plerixafor for PBSC mobilization, which
showed a success rate of 100%, without acute complica-
tions. This is a higher success rate than those in the
previous pediatric studies [3,7]. However we experienced
two patients with medulloblastoma, who suffered from
fatal pulmonary complication. Though the pathogenesis
was not understood, further studies are needed to inves-
tigate possible complications of plerixafor in pediatric
patients.
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Table 1 Patient Demographics and Prior Treatment Received
Pt
#
Dx Sex Age Earlier chemotherapy Earlier
radiotherapy
1st line mobilization
chemotherapy
1 NBL M 11 CDDP + VP16 + ADR + CPM, CPM + Topo + VP16 No CPM + VP16+ GCSF
2 MBL F 11 CDDP + CPM + VCR, CPM + VCR, Carbo + VP16 + IFM + VCR IFRT + CSI Carbo + VP16 + IFM +
VCR + GCSF
3 OSA M 6 CDDP + ADR + MTX, IFM + ADR + MTX No CPM + VP16+ GCSF
4 OSA F 10 CDDP + ADR + MTX, IFM + ADR + MTX, Gemcitabine + Doxetaxel, CPM + Topo +
VP16, IFM + Carbo + VP16
No CPM + VP16+ GCSF
5 MBL M 10 CDDP + CPM + VCR, CPM + VCR IFRT + CSI Carbo + VP16 + IFM +
VCR + GCSF
6 ES F 15 VCR + ADR + CPM, IFM + VP16 No CPM + VP16+ GCSF
ADR Doxorubicin, Carbo Carboplatin, CDDP Cisplatin, CPM cyclophosphamide, CSI Craniospinal axis irradiation, ES Ewing sarcoma, G-CSF Granulocyte colony
stimulating factor, IFM Ifosphamide, IFRT Involved field radiation therapy, LP Leukapheresis, MBL Medulloblastoma, MTX Methotrexate, NBL Neuroblastoma, OSA
Osteosarcoma, Pt Patient, Topo Topotecan, VCR Vincristine, VP16 Etoposide
Table 2 PBSC Collection and Engraftment
Plerixafor-based PBSC collection Engraftment
Pt
#
Prior CD34
yield (10
6 CD34 +
cells/kg)
Days for
LP
CD34+ cells
(10
6/kg)
TNC
(10
8/
kg)
Days for
LP
TPL
#
PBSC infused
(10
6 CD34+
cells/kg)
ANC > 500/mL
(days)
PLT > 20,000/mL
(transfusion-
independent)(days)
1 1.24 4 12.64 16.13 3 #1 5.91 10 35
#2 3.48 9 197
2 0.18 2 9.52 11.2 2 4.8 10 26
3 1.68 2 6.81 10.67 2 8.49 10 15
4 0.7 3 6.34 15.1 2 7.04 N/A N/A
5 4 4 28.97 20.25 2 17.78 10 N/A
6 0.8 3 15.25 17.83 2 3.74 12 18
ANC Absolute Neutrophil Count, LP Leukapheresis, N/A Not Applicable (due to early death), PBSC Peripheral Blood Stem Cell, PLT Platelet, Pt, Patient, TNC Total
Nuclear Cells, TPL Transplantation
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